Bayer's Stivarga approved for further indication in Japan
FRANKFURT Aug 20 (Reuters) - Germany's largest drugmaker Bayer said it received regulatory approval in Japan for the marketing of cancer treatment Stivarga for patients with gastrointestinal stromal tumours who have progressed after prior systemic cancer therapy.
Stivarga is already approved in several countries, including the United States and Japan, for the treatment of patients with metastatic colorectal cancer (mCRC), Bayer said on Tuesday.
It was recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with mCRC in June, with a decision by the European Commission on the marketing authorisation later this year. (Reporting by Maria Sheahan; Editing by Victoria Bryan)
- White House reverses, says Obama met uncle and lived with him during law school
- With song and sadness, South Africans mourn Mandela |
- U.S. television, Twitter, alive with new version of 'Sound of Music'
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image
- Ford leans on global Mustang to burnish overseas image